Your browser doesn't support javascript.
loading
Lenvatinib improves anti-PD-1 therapeutic efficacy by promoting vascular normalization via the NRP-1-PDGFRß complex in hepatocellular carcinoma.
Yang, Jieying; Guo, Zhixing; Song, Mengjia; Pan, Qiuzhong; Zhao, Jingjing; Huang, Yue; Han, Yulong; Ouyang, Dijun; Yang, Chaopin; Chen, Hao; Di, Muping; Tang, Yan; Zhu, Qian; Wang, Qijing; Li, Yongqiang; He, Jia; Weng, Desheng; Xiang, Tong; Xia, JianChuan.
Afiliação
  • Yang J; Department of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Guo Z; Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Song M; Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Pan Q; Department of Ultrasound, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
  • Zhao J; Department of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Huang Y; Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Han Y; Department of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Ouyang D; Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Yang C; Department of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Chen H; Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Di M; Department of Oncology and Translational Medicine Center, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
  • Tang Y; Guangzhou Laboratory, Guangzhou, China.
  • Zhu Q; Department of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Wang Q; Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Li Y; Department of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • He J; Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Weng D; Department of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Xiang T; Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Xia J; Department of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, China.
Front Immunol ; 14: 1212577, 2023.
Article em En | MEDLINE | ID: mdl-37545530
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas / Antineoplásicos Limite: Animals / Humans Idioma: En Revista: Front Immunol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas / Antineoplásicos Limite: Animals / Humans Idioma: En Revista: Front Immunol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China